Video

Dr. Hammers on Next Steps with Immunotherapy in RCC

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Data are still needed to determine the response of nivolumab (Opdivo) in certain subsets of patients, states Hammers. If there is a signal of clinical activity, it might be studied in combination with other regimens for this patient population.

Related Videos
Timothy S. Fenske, MD, MS
Ignacio Garrido-Laguna, MD, PhD, MBA
Marwan G. Fakih, MD
Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
Werutsky
Dr Sekkeres on the Association Between Smoking and Disease Progression in MDS
Lori Muffly, MD
Pooja Phull, MD
Eric Winer, MD